Ajanta Pharma files revised SAST disclosures for share encumbrance by Aayush Agrawal and Gabs Investments

What Ajanta Pharma announced

On 8 July 2026 Ajanta Pharma Ltd filed revised disclosures with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The revision corrects the earlier filing by specifying the exact entities – both lender and trustee – that hold encumbered shares of Ajanta Pharma. The company states that no other details in the original disclosure have been changed.

Details of the revised encumbrances

The revised table lists four rows of share encumbrance:

The filing notes that the original submission only mentioned the trustee’s name. The revised version now lists both the lender (e.g., Gabs Investments) and the trustee (e.g., Aayush Agrawal Trust) as required by the SEBI regulations.

Purpose of the pledges

All the encumbered shares are being used as collateral for the issuance of non‑convertible debentures (NCDs). The debentures are transferable instruments held by CTL Trusteeship Ltd on behalf of a set of investors that include the 360 ONE Income Opportunities Fund series and 360 ONE Prime Ltd. The filing explicitly states that the pledged shares serve as security for these NCDs and do not imply any sale or transfer of ownership.

Key facts at a glance

Why this matters for investors

The revised disclosure does not alter Ajanta Pharma’s share capital structure; it merely clarifies who holds the pledged shares on behalf of lenders. For shareholders, the key implications are:

• Voting rights – While the shares are pledged, the legal owner (the lender) retains voting rights unless the lender instructs otherwise. The filing does not indicate any change in voting arrangements.
• Potential dilution – The pledged shares remain part of the existing share pool. If the underlying debentures are converted or the pledges are released, the share count could change, but the filing does not project such events.
• Regulatory compliance – By updating the disclosures, Ajanta Pharma ensures compliance with SEBI’s requirement to disclose both lender and trustee, reducing the risk of regulatory penalties.
• Credit exposure – The pledges signal that the promoters and Gabs Investments have used their holdings to secure financing, which may affect their personal liquidity but does not directly impact the company’s balance sheet.

Conclusion

Ajanta Pharma’s filing on 8 July 2026 amends earlier SAST disclosures to correctly identify the lenders and trustees behind pledged shares amounting to roughly 3 % of its total equity. The pledges are tied to non‑convertible debentures held by CTL Trusteeship Ltd for institutional investors. No other material information was altered, and the company awaits the exchange’s acknowledgment of the revised submission.